Liminatus Pharma, Inc. (LIMN) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Liminatus Pharma, Inc. (LIMN) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Liminatus is a clinical-stage immuno-oncology company developing cancer immunotherapies, led by IBA101, a next-generation anti-CD47 antibody planned for a Phase 1 trial in advanced solid tumors, and IBC101, a CD19xCD22 bivalent CAR-T. The thesis is a high-risk, high-reward bet that one of its early programs eventually produces clinical data worth far more than today's micro-cap valuation (about $4 million as of October 16, 2026). The biggest risks are severe: the company has flagged going concern doubt, holds very little cash, needed a 1-for-50 reverse split in August 2026 to stay on Nasdaq, and would need heavy dilution just to keep operating.
LIMN stock price
As of 2026-11-16, Liminatus Pharma, Inc. (LIMN) last closed at $2.97, down 94.4% over the past year. Over the past 52 weeks it has traded between $2.52 and $102.50.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Liminatus Pharma, Inc.'s investor relations page. Walnut is informational, not investment advice.
LIMN key stats
At $2.97 on November 16, 2026, Liminatus Pharma, Inc. (LIMN) has a market cap of $4M.
- Market cap
- $4M
- Price to book
- 11.0
- Beta
- 0.78
Market cap, P/E and yield are measured at the $2.97 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Liminatus Pharma, Inc. (LIMN)?
The last two weeks for Liminatus Pharma, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- LIMN closed at $2.97 on November 16, 2026, up 9.6% over the past five trading days (from $2.71).
- On November 3, 2026, Liminatus Pharma, Inc. filed an 8-K with the SEC reporting a material agreement and an unregistered sale of shares (Item 1.01, Item 3.02). Read the 8-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Liminatus Pharma, Inc. (LIMN) do?
Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company based in Cerritos, California, focused on therapies that use the immune system to detect and attack cancer cells. Its lead candidate is IBA101, a humanized anti-CD47 monoclonal antibody intended as a next-generation immune checkpoint inhibitor, with an initial focus on advanced solid tumors including non-small cell lung cancer. The broader pipeline includes a Guanylyl Cyclase C (GCC) cancer vaccine program and, through its transaction with InnocsAI (governed by an amended definitive merger agreement), CAR-T and antibody candidates such as IBC101, a CD19xCD22 bivalent CAR-T for B-cell malignancies cleared for an early-phase study in Korea, plus a CS1 antibody platform. In August 2026 the company engaged Synex as contract research organization for the Phase 1/2a development of the CD19xCD22 CAR-T. The company has no approved products, generates no revenue, and Yahoo Finance lists a single employee.
Liminatus became a public company by merging with the special purpose acquisition company Iris Acquisition Corp and began trading on Nasdaq under the ticker LIMN on May 1, 2024. Since then it has operated under significant financial strain. For 2025 it reported zero revenue and a net loss of roughly $10.2 million, ending the year with only about $338,000 in cash and an accumulated deficit near $38.9 million, prompting management to disclose substantial doubt about its ability to continue as a going concern. A February 2026 equity and warrant financing raised roughly $3.4 million in net proceeds, and over the trailing twelve months to mid-2026 the net loss was about $12.5 million, with roughly $3.0 million of cash and $1.4 million of debt at June 30. On listing status, Nasdaq notified the company in January 2026 that its stock had closed below $1.00 for 30 business days, and in May 2026 it received a delisting determination, which it appealed. The Hearings Panel moved the stock to the Nasdaq Capital Market effective August 4, 2026 and extended the deadline. Stockholders approved a 1-for-50 reverse split, effective after the close on August 20, 2026, which cut the share count from about 67.2 million to about 1.34 million. The stock then closed above $1.00 for 13 straight sessions, and on September 24 Nasdaq told the company the bid-price matter was closed. By October 16, 2026 the shares traded near $3.11, close to their post-split low.
What's driving Liminatus Pharma, Inc. (LIMN)?
1. Lead anti-CD47 program.
IBA101 is positioned as a next-generation CD47-blocking monoclonal antibody, a class designed to remove the 'don't eat me' signal that tumors use to evade immune cells. The company has announced plans to initiate a Phase 1 trial in advanced solid tumors, including non-small cell lung cancer. Positive early safety and signal data would be the main catalyst for the stock. CD47 is a well-studied but historically difficult target where several larger programs have struggled.
2. Pipeline breadth and the InnocsAI deal.
Beyond IBA101, Liminatus has described a Guanylyl Cyclase C cancer vaccine program and, through InnocsAI, CAR-T and antibody candidates, including IBC101, a CD19xCD22 bivalent CAR-T cleared for an early-phase study in Korea. Hiring Synex in August 2026 as the CRO for its Phase 1/2a development is the most concrete clinical step the company has announced this year. A wider pipeline spreads the bet across more shots on goal. It also adds complexity, integration risk, and likely large share issuance to fund and complete the deal.
3. Financing is the immediate driver.
With cash measured in low single-digit millions (about $3.0 million at June 30, 2026), trailing operating cash outflow near $4 million, and a going concern warning, Liminatus depends on continued capital raises to operate. Each raise tends to come at depressed prices and dilutes existing holders, so the timing, size, and terms of the next financing matter more to the share price right now than any clinical readout. With only about 1.34 million shares outstanding after the reverse split, even a small offering can be large relative to the existing float.
4. Nasdaq listing after the reverse split.
The 1-for-50 reverse split did its job on the bid-price rule: the stock closed above $1.00 for 13 consecutive sessions from August 21 to September 9, 2026, and Nasdaq closed the matter on September 24. That removed the most immediate delisting threat. It does not change the business, though, and reverse splits in distressed micro-caps are often followed by further declines; LIMN fell about 11% in the month to October 16 and sits near its 52-week low of about $3.01, so listing standards could come back into focus if the slide continues.
What are the risks to Liminatus Pharma, Inc. (LIMN)?
Liminatus carries the full stack of risks that define a distressed pre-revenue biotech. It has no products and no revenue, an accumulated deficit above $40 million, and management has disclosed substantial doubt about its ability to continue as a going concern, meaning it may be unable to fund operations without raising more capital on potentially harsh terms. Its lead asset, IBA101, is still early and unproven, and CD47 is a target where larger, better-funded programs have repeatedly failed, so a single clinical setback could be decisive given how concentrated the value is in a handful of early programs. The company regained Nasdaq bid-price compliance in September 2026 only through a 1-for-50 reverse split, and continued financings, plus the share issuance tied to the InnocsAI transaction, point to heavy dilution. The stock is a micro-cap worth about $4 million with low liquidity and extreme volatility: on a split-adjusted basis it is down about 90% year to date and about 95% over one year, with a 52-week range of roughly $3.01 to $141.50. A total loss is a realistic outcome.
Is LIMN a buy or a sell?
We give no verdict on Liminatus Pharma, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Lead anti-CD47 program. IBA101 is positioned as a next-generation CD47-blocking monoclonal antibody, a class designed to remove the 'don't eat me' signal that tumors use to evade immune cells.
The case against. Liminatus carries the full stack of risks that define a distressed pre-revenue biotech.
Read the full bull and bear case on LIMN, including what would have to change to break either one. Walnut is not an investment adviser.
Has Liminatus Pharma, Inc. (LIMN) split its stock?
Yes. Liminatus Pharma, Inc. (LIMN) has had one share split in the last 10 years:
- 1:50 on August 21, 2026, so every share held became 0.02 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of LIMN the day before the 1:50 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Liminatus Pharma, Inc. (LIMN) valued?
Market cap, P/E and dividend yield at today's price are in the LIMN key stats above. The business figures below come from Liminatus Pharma, Inc.'s reported results as of October 2026 (financials through the quarter ended June 30, 2026) and change when it next reports.
- Revenue: $0 (no approved products)
- Net loss (TTM): ~$12.5 million
- Net loss (FY2025): ~$10.2 million
- Cash / debt: ~$3.0 million / ~$1.4 million (Jun 30, 2026)
- Shares outstanding: ~1.34 million after the 1-for-50 reverse split
As of October 2026 (financials through the quarter ended June 30, 2026): For a clinical-stage biotech with no revenue, traditional metrics like P/E or price-to-sales do not apply, so the numbers that matter are cash on hand, the cash burn, and the runway between them. Here the runway is very short: a trailing net loss of about $12.5 million and operating cash outflow near $4 million against roughly $3 million in cash means the company must keep raising money to operate, which is why management disclosed going concern doubt. Read the roughly $4 million market cap as the market's small, heavily discounted estimate of a binary pipeline rather than a multiple of any earnings, and treat each financing and clinical update as the real value driver.
Who competes with Liminatus Pharma, Inc. (LIMN)?
CD47-focused immuno-oncology developers
Companies advancing CD47 or related 'don't eat me' checkpoint programs, such as Gilead's Forty Seven legacy assets and ALX Oncology (ALXO), pursue the same biological target as IBA101 with far larger resources.
Clinical-stage cell therapy and cancer vaccine biotechs
CAR-T and cancer-vaccine developers like Legend Biotech (LEGN), CRISPR Therapeutics (CRSP), and other early oncology names compete for the same scientific talent, trial sites, and investor capital that fund Liminatus's broader pipeline, including its CD19xCD22 bivalent CAR-T.
Diversified biotech ETFs and alternatives
For exposure to early-stage oncology without single-company risk, broad biotech funds such as the SPDR S&P Biotech ETF (XBI) or iShares Biotechnology ETF (IBB) spread the bet across many drug developers, smoothing the binary outcomes that dominate a name like LIMN.
What stocks are similar to Liminatus Pharma, Inc. (LIMN)?
Other names that sit close to LIMN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Liminatus Pharma, Inc. (LIMN)
There are three common ways to get LIMN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so LIMN sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where LIMN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Liminatus Pharma, Inc. (LIMN)
Liminatus Pharma is a distressed, pre-revenue micro-cap biotech whose value depends almost entirely on future clinical milestones it has not yet reached, with no products, no revenue, and ongoing going concern risk. The reverse split cured its Nasdaq bid-price problem in September 2026, but the share price has kept falling since, and the stock is down about 90% in 2026 on a split-adjusted basis. In a portfolio it behaves like a binary option on its early-stage pipeline, capable of large percentage swings on financing and trial news while carrying a real chance of going to zero.
More on Liminatus Pharma, Inc. (LIMN)
Whether LIMN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LIMN a buy or a sell?, and where the stock could go from here in the LIMN stock forecast.
For income investors, whether LIMN pays a dividend and how the payout looks is covered in does LIMN pay a dividend? And to weigh LIMN against a peer, read the full side-by-side comparisons: LIMN vs GILD and LIMN vs CAR.
Wondering how LIMN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Liminatus Pharma, Inc.
Ask Walnut's AI anything about LIMN and see how it fits what you own.
FAQ
What does Liminatus Pharma do?
+
Liminatus Pharma is a clinical-stage immuno-oncology company developing therapies that use the immune system to fight cancer. Its lead candidate, IBA101, is a next-generation anti-CD47 monoclonal antibody planned for a Phase 1 trial in advanced solid tumors, and its broader pipeline includes a GCC cancer vaccine and, via InnocsAI, CAR-T programs such as IBC101. It has no approved products and no revenue.
Does LIMN pay a dividend?
+
No. Liminatus Pharma does not pay a dividend. It is a pre-revenue clinical-stage biotech that is burning cash on research and operations and has disclosed going concern doubt, so any available capital goes toward funding the business rather than shareholder payouts. Investors in this kind of company are betting on future clinical progress, not income.
Why did LIMN get a Nasdaq delisting notice?
+
Nasdaq notified Liminatus in January 2026 that its stock had closed below $1.00 for 30 consecutive business days, and in May 2026 it received a formal delisting determination. The company appealed, and the Hearings Panel moved it to the Nasdaq Capital Market on August 4, 2026 with an extended deadline. After a 1-for-50 reverse split on August 20, the stock closed above $1.00 for 13 straight sessions, and on September 24, 2026 Nasdaq said the bid-price matter was closed.
What is IBA101?
+
IBA101 is Liminatus Pharma's lead drug candidate, a humanized anti-CD47 monoclonal antibody designed as a next-generation immune checkpoint inhibitor. CD47 is a 'don't eat me' signal tumors use to avoid immune attack, and the company plans to study IBA101 in advanced solid tumors, including non-small cell lung cancer. It is early stage and unproven in trials.
Is LIMN a profitable company?
+
No. Liminatus has no revenue and reported a net loss of about $10.2 million for 2025 and about $12.5 million over the twelve months to June 2026, with an accumulated deficit above $40 million. Like most clinical-stage biotechs, it is expected to keep losing money until and unless it can develop and commercialize a drug, which is far from guaranteed.
Is LIMN a good stock?
+
This is descriptive, not advice. The bull case is that a market value of about $4 million could multiply if an early program like IBA101 or IBC101 produces meaningful clinical data. The bear case is severe: going concern doubt, very little cash, heavy dilution, a recent reverse split, and a real chance of going to zero. Whether it fits you depends on your own goals and risk tolerance.
Is LIMN a good stock to buy right now?
+
This is informational, not a recommendation. Liminatus is a highly speculative, distressed micro-cap whose near-term path is driven by financings and listing status rather than fundamentals, and it can move sharply in either direction. Some investors treat such names as small, high-risk bets, while others avoid them entirely. Walnut provides information, not investment advice.
Which ETFs or baskets include LIMN?
+
Because Liminatus is a very small, distressed micro-cap, it is unlikely to be a meaningful holding in major biotech ETFs like XBI or IBB, which weight toward larger companies. Some broad or micro-cap index funds may hold a tiny position. In Walnut you can add LIMN as one constituent of a thematic basket, for example an early-stage immuno-oncology theme, alongside other names.
Did Liminatus do a reverse stock split?
+
Yes. Stockholders approved a 1-for-50 reverse split at the August 3, 2026 annual meeting, and it took effect after the close on August 20, 2026, with split-adjusted trading from August 21 under the same LIMN ticker. It reduced the share count from about 67.2 million to about 1.34 million, with fractional shares rounded up. Historical prices are adjusted, which is why the 52-week high shows as about $141.50.
How has LIMN stock performed in 2026?
+
Very poorly. On a split-adjusted basis, LIMN closed near $3.11 on October 16, 2026, down about 90% year to date, about 95% over one year, and about 48% over the past three months, sitting just above its 52-week low of about $3.01. No analysts publish estimates or price targets on the stock.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Liminatus Pharma, Inc.'s investor relations page or your broker before making investment decisions.